ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis.
Humans
Female
Angiotensin-Converting Enzyme Inhibitors
/ therapeutic use
Cardiotoxicity
/ etiology
Antineoplastic Agents
/ adverse effects
Breast Neoplasms
/ drug therapy
Trastuzumab
/ adverse effects
Angiotensin Receptor Antagonists
/ therapeutic use
Antibiotics, Antineoplastic
/ therapeutic use
Anthracyclines
/ adverse effects
Randomized Controlled Trials as Topic
ACEI/ARB
Beta-blocker
Breast cancer
Cardiotoxicity
LVEF
Journal
Heart failure reviews
ISSN: 1573-7322
Titre abrégé: Heart Fail Rev
Pays: United States
ID NLM: 9612481
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
accepted:
06
06
2023
medline:
23
10
2023
pubmed:
7
7
2023
entrez:
6
7
2023
Statut:
ppublish
Résumé
Anthracyclines and trastuzumab are widely used to treat breast cancer but increase the risk of cardiomyopathy and heart failure. With the use of trastuzumab and anthracycline-containing medications, this study intends to evaluate the effectiveness and security of current treatments against cardiotoxicity. We conducted a systematic review of randomized controlled trials (RCTs), which used at least one angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or beta-blocker (BB) to prevent cardiotoxicity of antineoplastic agents for breast cancer, in 4 databases (PubMed, Cochrane Library, EMBASE, Web of Science) from inception to 11 May 2022, without language restrictions. The outcome of interest was left ventricular ejection fraction (LVEF) and adverse events. Stata 15 and R software 4.2.1 were used to perform all statistical analyses. The Cochrane version 2 of the risk of bias tool was used to assess the risk of bias, and the grading of recommendations assessment, development, and evaluation (GRADE) assessment was used to appraise the quality of the evidence. Fifteen randomized clinical studies with a total of 1977 patients were included in the analysis. The included studies demonstrated statistically significant LVEF in the ACEI/ARB and BB treatment groups (χ
Identifiants
pubmed: 37414918
doi: 10.1007/s10741-023-10328-z
pii: 10.1007/s10741-023-10328-z
pmc: PMC10575808
doi:
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
Antineoplastic Agents
0
Trastuzumab
P188ANX8CK
Angiotensin Receptor Antagonists
0
Antibiotics, Antineoplastic
0
Anthracyclines
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1405-1415Informations de copyright
© 2023. The Author(s).
Références
Cancers (Basel). 2019 Jun 28;11(7):
pubmed: 31261758
J Clin Oncol. 2011 Jan 10;29(2):149-56
pubmed: 21115860
Cancer. 2002 Oct 1;95(7):1592-600
pubmed: 12237930
Int J Cardiol. 2013 Sep 1;167(5):2306-10
pubmed: 22727976
Ann Oncol. 2020 Feb;31(2):171-190
pubmed: 31959335
Eur Heart J. 2016 Jun 1;37(21):1671-80
pubmed: 26903532
Ann Oncol. 2017 Mar 1;28(3):628-633
pubmed: 28028033
J Am Coll Cardiol. 2019 Jun 11;73(22):2859-2868
pubmed: 31171092
Cardiooncology. 2021 Sep 27;7(1):33
pubmed: 34579775
Int J Hematol Oncol Stem Cell Res. 2021 Oct 1;15(4):206-212
pubmed: 35291664
J Am Heart Assoc. 2020 Sep 15;9(18):e018403
pubmed: 32893704
Cardiovasc Toxicol. 2017 Apr;17(2):130-139
pubmed: 27003392
J Clin Oncol. 2017 Mar 10;35(8):870-877
pubmed: 27893331
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
J Cardiol. 2020 Feb;75(2):140-147
pubmed: 31444140
JAMA Oncol. 2021 Oct 01;7(10):1544-1549
pubmed: 34436523
Eur Heart J. 2022 Jul 14;43(27):2562-2569
pubmed: 34951629
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Cardiology. 2016;134(1):47-53
pubmed: 26866364
JACC CardioOncol. 2019 Sep 24;1(1):68-79
pubmed: 34396164
J Cardiovasc Pharmacol. 2017 May;69(5):279-285
pubmed: 28141699
J Clin Oncol. 2017 Oct 10;35(29):3298-3305
pubmed: 28727517
Crit Rev Oncol Hematol. 2020 Sep;153:103006
pubmed: 32777728
Breast Cancer Res Treat. 2014 Jul;146(2):411-9
pubmed: 24951268
JAMA Oncol. 2016 Aug 1;2(8):1030-7
pubmed: 27348762
Cancer Manag Res. 2018 Jul 16;10:2071-2081
pubmed: 30038521
J Am Coll Cardiol. 2020 Nov 10;76(19):2267-2281
pubmed: 33153587
Cancer Med. 2021 Jun;10(12):3964-3973
pubmed: 33998163
Asian Pac J Cancer Prev. 2021 Sep 01;22(9):2847-2853
pubmed: 34582653
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2672-2680
pubmed: 30692261
J Am Coll Cardiol. 2018 May 22;71(20):2281-2290
pubmed: 29540327
Cardiol J. 2014;21(5):509-15
pubmed: 24142687